Head to head
Hexarelin vs Ipamorelin
Side-by-side on muscle growth, dosing, kinetics and evidence — with an honest verdict at the end.
Verdict
No winner in this data
What you are actually choosing between
Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.
The overlap is muscle growth, recovery and sleep, and injury repair. On this site's goal weighting — an editorial priority score, not a measure of effect size — Hexarelin rates 4/5 for muscle growth and Ipamorelin rates 3/5.
The evidence
Hexarelin sits one step firmer: controlled human trials behind it, without an approval — human GH-response data is real, but the response blunts within weeks. Ipamorelin has some human data, but it is small, old, or uncontrolled — small early-phase work only; development was discontinued. One tier is a real difference but not a decisive one; it should not on its own settle the choice.
How they differ in practice
Hexarelin is a subcutaneous injection and an intramuscular injection; Ipamorelin is a subcutaneous injection. Both are injected, so route does not decide this one.
Half-lives are close — 1 h for Hexarelin, 2 h for Ipamorelin — and both are dosed once daily, so the rhythm of actually running them is the same.
Committed time differs: Hexarelin runs 4 weeks, Ipamorelin runs 12 weeks.
Risk and difficulty
Ipamorelin is rated beginner here and Hexarelin advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.
Source notes
What the evidence actually says
Verbatim, so you can check the verdict above against what it was built from.
Hexarelin
Synthetic hexapeptide ghrelin receptor (GHS-R1a) agonist and one of the most potent GH secretagogues studied in humans, with additional cardiac data. Its defining practical problem is tachyphylaxis: repeated dosing blunts the GH response over roughly two to four weeks, which is why it is cycled short rather than run continuously. It also lacks the selectivity of ipamorelin, so prolactin and cortisol elevation are expected at higher doses.
Ipamorelin
Selective ghrelin receptor (GHS-R1a) agonist that triggers a growth hormone pulse with little effect on cortisol or prolactin, which is the main reason it is chosen over hexarelin or GHRP-6. Published human work is limited to small early-phase and post-operative ileus studies; development was discontinued and it is NOT an approved medicine anywhere. Everything sold to consumers is research-chemical grade, so the community 100-300 mcg per dose range comes from practice rather than from a label.
Side by side
The numbers
| Attribute | Hexarelin | Ipamorelin |
|---|---|---|
| Class | GH secretagogue | GH secretagogue |
| Routes | Subcutaneous, Intramuscular | Subcutaneous |
| Dose range | 50 mcg–200 mcg (typical 100 mcg) | 100 mcg–300 mcg (typical 200 mcg) |
| Frequency | Once daily | Once daily |
| Half-life | 1 h | 2 h |
| Cycle length | 4 weeks | 12 weeks |
| Experience | Advanced | Beginner |
| Evidence | Controlled human trials | Limited human data |
| Contraindications |
|
|
| Side effects |
|
|
Turn a typical dose into a mark on the syringe: HexarelinIpamorelin
Goals
Where they overlap, and where they do not
| Goal | Hexarelin | Ipamorelin |
|---|---|---|
| muscle growth | Hexarelin: 4/5 | Ipamorelin: 3/5 |
| recovery and sleep | Hexarelin: 3/5 | Ipamorelin: 4/5 |
| injury repair | Hexarelin: 3/5 | Ipamorelin: 3/5 |
| fat loss | Hexarelin: 2/5 | Ipamorelin: 2/5 |
| longevity | Hexarelin: 1/5 | Ipamorelin: 2/5 |
They overlap on 5 goals and diverge on 0. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.
Next
Go deeper
Related
Other comparisons with these two
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.